Strides receives USFDA approval for Potassium Chloride for Oral Solution

Strides Pharma Science Limited (Strides) today announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride for Oral Solution USP, 20 mEq, of Pharma Research Software Solution, LLC.

According to IQVIA MAT January 2021 data, the US market for Potassium Chloride for Oral Solution USP, 20 mEq is approximately US$ 56 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with USFDA of which 100 ANDAs have been approved and 27 are pending approval.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.806.7 as compared to the previous close of Rs. 802.4. The total number of shares traded during the day was 115021 in over 2349 trades.

The stock hit an intraday high of Rs. 819 and intraday low of 794.7. The net turnover during the day was Rs. 93207147.

Source : Equity Bulls

Keywords